Relmada Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -19,051 | -19,867 | -10,091 | -9,866 |
Net Income | -19,051 | -19,867 | -10,091 | -9,866 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -15,067 | -14,596 | -6,721 | -6,401 |
Cash | 9,776 | 3,496 | 1,384 | 1,353 |
Basic Shares | 86,596 | 68,255 | 33,191 | 33,191 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -57,385 | -79,979 | 4,910 | -157,041 |
EBIT | -79,979 | -98,792 | -157,043 | |
Net Income | -57,385 | -79,979 | -98,792 | -157,043 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -39,047 | |||
Free Cash Flow | -45,786 | -51,755 | -51,659 | -103,801 |
Cash | 3,496 | 3,857 | 4,091 | 5,395 |
Basic Shares | 39,479 | 30,164 | 30,099 | 29,629 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.22 |
2025-12-31 | -$0.29 |
2025-09-30 | -$0.30 |
2025-06-30 | -$0.30 |